

Richard Iggo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6617462/publications.pdf>

Version: 2024-02-01

12
papers

2,513
citations

1170033

9
h-index

1427216

11
g-index

13
all docs

13
docs citations

13
times ranked

4255
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction of an interferon response by RNAi vectors in mammalian cells. <i>Nature Genetics</i> , 2003, 34, 263-264.	9.4	907
2	Identification of molecular apocrine breast tumours by microarray analysis. <i>Oncogene</i> , 2005, 24, 4660-4671.	2.6	694
3	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. <i>Nature Medicine</i> , 2009, 15, 68-74.	15.2	566
4	The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. <i>Nature Medicine</i> , 2021, 27, 310-320.	15.2	122
5	TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2011, 12, 527-539.	5.1	116
6	Post-transcriptional Gene Regulation by MicroRNA-194 Promotes Neuroendocrine Transdifferentiation in Prostate Cancer. <i>Cell Reports</i> , 2021, 34, 108585.	2.9	33
7	The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours. <i>Journal of Pathology</i> , 2016, 240, 256-261.	2.1	31
8	Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer. <i>British Journal of Cancer</i> , 2015, 113, 585-594.	2.9	23
9	Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes. <i>British Journal of Cancer</i> , 2019, 120, 913-921.	2.9	11
10	Lentiviral Transduction of Mammary Epithelial Cells. <i>Methods in Molecular Biology</i> , 2022, 2471, 159-183.	0.4	4
11	Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer. <i>British Journal of Cancer</i> , 2021, 125, 1356-1364.	2.9	3
12	Modeling Breast Cancer in Organoid and Intraductal Models. <i>Methods in Molecular Biology</i> , 2022, 2471, 235-257.	0.4	1